Skip to main navigation

Top bar

Biogen.com Information Request Sign up for Alerts Search

Investor Relations

Overview

News

Events Presentations

SEC Filings Annual Reports

Stock Quote & Chart Analyst Coverage Investor FAQs

Governance Documents Committee Composition & Charters Leadership Code of Business Conduct Contact the Board

News

News

News Category

Year

May 30, 2019

New Phase 3 Interim Results Support Safety and Efficacy of Diroximel Fumarate in Multiple Sclerosis

May 21, 2019

Biogen to Present at Bernstein’s 35th Annual Strategic Decisions Conference

May 20, 2019

Biogen Recommends Stockholders Reject the Below-market Mini-tender Offer by TRC Capital Corporation

May 15, 2019

Biogen to Host Investor Webcast to Discuss ALS Portfolio on June 5, 2019

May 14, 2019

Biogen’s SPINRAZA® (nusinersen) Receives Positive Recommendation from NICE for Funding in the United Kingdom for the Treatment of Infants, Children and Adults with Spinal Muscular Atrophy

May 7, 2019

Data at AAN Demonstrate Biogen’s Leadership and Commitment to Innovation in MS

May 6, 2019

Biogen Presents Data at 2019 AAN Annual Meeting Affirming Longer-Term Safety and Durability of Treatment with SPINRAZA® (nusinersen)

May 1, 2019

Biogen to Present New Interim Data from Its Phase 1/2 Clinical Study of Tofersen (BIIB067) for the Potential Treatment of a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS)

May 1, 2019

Biogen To Present Data At AAN Highlighting Its Innovative Marketed Treatments And Investigational Pipeline Programs For Complex Neurodegenerative Diseases

April 30, 2019

Data Published in Neurology Show that Treatment with SPINRAZA® (nusinersen) Improved Motor Function and Provided Long-Term Benefit for Individuals with Later-Onset Spinal Muscular Atrophy

Pagination

First page
Previous page
…
Page 8
Page 9
Page 10
Page 11
Current page 12
Page 13
Page 14
Page 15
Page 16
…
Next page
Last page

Displaying 111 - 120 of 784

Footer

Investors
Careers
Our Stories
Contact Us

Follow us

Bottom

Privacy Policy
Terms & Conditions
Forward-Looking Statements
Community Guidelines

Investor Relations

Overview

News

Events & Presentations

Events
Presentations

Financials

SEC Filings
Annual Reports

Stock Information

Stock Quote & Chart
Analyst Coverage
Investor FAQs

Corporate Governance

Governance Documents
Committee Composition & Charters
Leadership
Code of Business Conduct
Contact the Board

Top bar

Biogen.com

Information Request

Sign up for Alerts

Search

Follow us